Notably, knockdown or inhibition of CHD1L consistently sensitizes tumor cells to chemotherapy and other targeted therapies, even in previously resistant models, positioning CHD1L as a compelling target to overcome MDR in a multitude of cancers [2, 16–18, 75, 76]. The gene discussed is CHD1L; the disease is neoplasm.